Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
30.80
+0.40 (+1.32%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NovoCure Limited - Ordinary Shares
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
17
18
Next >
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
Why Novocure Stock Was so Healthy Today
February 15, 2023
There was good news from the laboratory on Hump Day.
Via
The Motley Fool
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
February 15, 2023
From
Novocure
Via
Business Wire
Why Novocure Stock Is Sliding Today
January 19, 2023
Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.
Via
The Motley Fool
Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes
January 19, 2023
A series of unexpected C-suite changes sent shares diving again.
Via
Investor's Business Daily
Novocure Announces Organizational Changes to Prepare for Future Growth
January 19, 2023
From
Novocure
Via
Business Wire
Will Novocure Stock Sink or Soar in 2023?
January 19, 2023
The stock has both soared and sank already this year.
Via
The Motley Fool
Why Novocure Stock Is Sinking Today
January 09, 2023
The company provided a disappointing sneak peek at its Q4 results.
Via
The Motley Fool
Why Novocure Stock Is Flying High
January 06, 2023
Here's why Novocure stock popped over 68% on Jan. 5.
Via
The Motley Fool
Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace
January 17, 2023
Shares have given back a chunk of their 69% single-day gain on a lung cancer study.
Via
Investor's Business Daily
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
January 09, 2023
From
Novocure
Via
Business Wire
Is NovoCure a Good Stock to Buy Right Now?
January 07, 2023
Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?
Via
The Motley Fool
Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review
January 06, 2023
The major indexes rallied Friday on the jobs report and services data.
Via
Investor's Business Daily
Why Novocure Stock Is Skyrocketing Today
January 05, 2023
The company announced good news from a late-stage study of its Tumor Treating Fields therapy.
Via
The Motley Fool
Novocure Skyrockets After Pulling Off A Once-In-Six-Years Feat
January 05, 2023
The company is now planning to ask for FDA approval in the second half of 2023.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
Tesla, Amazon, Aehr, Silvergate, Novocure: Why These 5 Stocks Are Drawing Investors' Attention Today
January 05, 2023
Major Wall Street indices closed over 1% lower on Thursday, dragged by strong employment data which could nudge the Federal Reserve to continue its rate hikes.
Via
Benzinga
Why Shares of Zai Lab Soared This Week
January 05, 2023
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.
Via
The Motley Fool
Dow Falls Over 200 Points; Walgreens Earnings Top Expectations
January 05, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 200 points on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 05, 2023
Via
Benzinga
Nasdaq Down Over 100 Points; Crude Oil Rises 1%
January 05, 2023
U.S. stocks traded lower midway through trading, with the Nasdaq Composite shedding more than 100 points on Thursday.
Via
Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 05, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...
Via
Benzinga
Why Is Huadi International (HUDI) Stock Up 30% Today?
January 05, 2023
Huadi International (HUDI) stock is climbing higher on Thursday even without specific news from the Chinese steel company.
Via
InvestorPlace
Why Is Magic Empire Global (MEGL) Stock Up 83% Today?
January 05, 2023
Magic Empire Global (MEGL) stock is rocketing higher on Thursday despite a lack of news from the Hong Kong financial services provider.
Via
InvestorPlace
NovoCure (NVCR) Stock Soars 50% on Positive Clinical Trial Results
January 05, 2023
NVCR stock traders are undeniably pleased to see NovoCure marking a milestone in the company's quest to treat a specific type of lung cancer.
Via
InvestorPlace
Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients
January 05, 2023
Via
Benzinga
This Good News on Cancer Sent 2 Nasdaq Stocks Soaring
January 05, 2023
Biotech investors are optimistic about the prospects for a potential treatment.
Via
The Motley Fool
US Stocks Open Lower; Dow Tumbles 300 Points
January 05, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 300 points on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 05, 2023
Via
Benzinga
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Zai Lab Limited
Via
GlobeNewswire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.